These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23210283)

  • 1. [Radionuclide therapy for cancer--what's new?].
    Hanna M; Mikko T
    Duodecim; 2012; 128(21):2209-16. PubMed ID: 23210283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
    Bomanji JB; Papathanasiou ND
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective internal radiotherapy (radioembolization) and radiation therapy for HCC--current status and perspectives].
    Hilgard P; Müller S; Hamami M; Sauerwein WS; Haberkorn U; Gerken G; Antoch G
    Z Gastroenterol; 2009 Jan; 47(1):37-54. PubMed ID: 19156591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
    Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM
    J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687
    [No Abstract]   [Full Text] [Related]  

  • 5. Radionuclide therapy beyond radioiodine.
    Gabriel M
    Wien Med Wochenschr; 2012 Oct; 162(19-20):430-9. PubMed ID: 22815123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    Forrer F; Riedweg I; Maecke HR; Mueller-Brand J
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):334-40. PubMed ID: 18480742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
    Jimenez C; Núñez R; Wendt R
    Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):162-169. PubMed ID: 32250976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New advances in peptide receptor radionuclide therapy.
    de Jong M; Krenning E
    J Nucl Med; 2002 May; 43(5):617-20. PubMed ID: 11994523
    [No Abstract]   [Full Text] [Related]  

  • 11. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics.
    Salem R; Thurston KG
    J Vasc Interv Radiol; 2006 Sep; 17(9):1425-39. PubMed ID: 16990462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
    Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R
    Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases.
    Stubbs RS; Cannan RJ; Mitchell AW
    Hepatogastroenterology; 2001; 48(38):333-7. PubMed ID: 11379303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.
    Kennedy AS; Salem R
    Cancer J; 2010; 16(2):163-75. PubMed ID: 20404614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective internal radiotherapy (SIRT) for hepatocellular carcinoma].
    Antoch G; Mueller SP; Hamami M; Heusner TA; Ertle J; Hilgard P; Forsting M; Bockisch A
    Rofo; 2010 Aug; 182(8):660-70. PubMed ID: 20405369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radioembolization with (90)Y-labeled microspheres: post-therapeutic therapy validation with Bremsstrahlung-SPECT].
    Grober OS; Nultsch M; Laatz K; Ulrich G; Seidensticker R; Pethe A; Dudeck O; Pech M; Knoop BO; Ricke J; Amthauer H; Geworski L
    Z Med Phys; 2011 Dec; 21(4):274-80. PubMed ID: 21719264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Cybulla M; Weiner SM; Otte A
    Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
    Jadvar H
    AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.